American Society of Gene & Cell Therapy Annual Meeting (ASGCT)

The company’s presence at ASGCT included not only a booth on the show floor, but also one oral and nine poster presentations.

A late-breaking poster presented at ASGCT 2025 described the enhanced central nervous system transduction and safety of the vector.

A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.

Tevard's tRNA therapy appears to restore full-length dystrophin and motor function in a Duchenne muscular dystrophy model, showing promise for nonsense mutation treatments.

The poster presentations contain data highlighting the company’s role to date in developing non-replicating HSV-1 technology for use in neurology.

BioPharm International® spoke with Ryan Larson, PhD, SVP, Head of Research at Umoja BioPharma about how emerging modalities in oncology treatments, including cell therapies, are evolving.

The company has had abstracts accepted for three oral presentations and five posters.

The company hopes that its proprietary circVec technology platform will become a gold standard for nucleic acid and viral therapeutics.